Anti-SEZ6L monoclonal antibody

Pre-made anti-SEZ6L monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SEZ6L/SEZ6L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1619-Ab-1/ GM-Tg-hg-IP1619-Ab-2Anti-Human SEZ6L monoclonal antibodyHuman
GM-Tg-rg-IP1619-Ab-1/ GM-Tg-rg-IP1619-Ab-2Anti-Rat SEZ6L monoclonal antibodyRat
GM-Tg-mg-IP1619-Ab-1/ GM-Tg-mg-IP1619-Ab-2Anti-Mouse SEZ6L monoclonal antibodyMouse
GM-Tg-cynog-IP1619-Ab-1/ GM-Tg-cynog-IP1619-Ab-2Anti-Cynomolgus/ Rhesus macaque SEZ6L monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1619-Ab-1/ GM-Tg-felg-IP1619-Ab-2Anti-Feline SEZ6L monoclonal antibodyFeline
GM-Tg-cang-IP1619-Ab-1/ GM-Tg-cang-IP1619-Ab-2Anti-Canine SEZ6L monoclonal antibodyCanine
GM-Tg-bovg-IP1619-Ab-1/ GM-Tg-bovg-IP1619-Ab-2Anti-Bovine SEZ6L monoclonal antibodyBovine
GM-Tg-equg-IP1619-Ab-1/ GM-Tg-equg-IP1619-Ab-2Anti-Equine SEZ6L monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1619-Ab-1/ GM-Tg-hg-IP1619-Ab-2; GM-Tg-rg-IP1619-Ab-1/ GM-Tg-rg-IP1619-Ab-2;
GM-Tg-mg-IP1619-Ab-1/ GM-Tg-mg-IP1619-Ab-2; GM-Tg-cynog-IP1619-Ab-1/ GM-Tg-cynog-IP1619-Ab-2;
GM-Tg-felg-IP1619-Ab-1/ GM-Tg-felg-IP1619-Ab-2; GM-Tg-cang-IP1619-Ab-1/ GM-Tg-cang-IP1619-Ab-2;
GM-Tg-bovg-IP1619-Ab-1/ GM-Tg-bovg-IP1619-Ab-2; GM-Tg-equg-IP1619-Ab-1/ GM-Tg-equg-IP1619-Ab-2
Products NameAnti-SEZ6L monoclonal antibody
Formatmab
Target NameSEZ6L
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SEZ6L monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1619-Ag-1Recombinant multi-species SE6L1/ SEZ6L protein


    Target information

    Target IDGM-IP1619
    Target NameSEZ6L
    Gene ID23544,56747,304554,714925,486329,101090650,520525,100065261
    Gene Symbol and SynonymsAcig1,AIG1,BSRP-B,mKIAA0927,RGD1563628,SEZ6L
    Uniprot AccessionQ9BYH1
    Uniprot Entry NameSE6L1_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000100095
    Target ClassificationN/A

    The target: SEZ6L, gene name: SEZ6L, also named as . Predicted to act upstream of or within adult locomotory behavior; nervous system development; and regulation of protein kinase C signaling. Predicted to be located in endoplasmic reticulum and neuronal cell body. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.